LLY shares trade above key support at $1033.50 and near 52-week highs after a 2.8% pullback, are held as 6.7% of AUM in top funds, and face a technical upside target at $1350.

Revenue surged over 40% year-over-year, driven by blockbuster Mounjaro and Zepbound sales, while adjusted operating margin expanded by over 21 percentage points. Management is guiding $80–83 billion in 2026 revenue and has built a $1.5 billion pre-launch inventory for its oral GLP-1 pill orforglipron, alongside a $1 billion investment to expand manufacturing capacity in India.

Medicare and Medicaid now extend coverage for GLP-1 weight-loss drugs under federal policy, while the FDA has approved new immunology indications (Omvoh for ulcerative colitis and Crohn’s disease) and combination psoriasis-obesity regimens. Exclusive licensing agreements for novel therapies (clazakizumab, gene and CAR-T modalities) and AI-driven partnerships are streamlining commercialization paths. Global supply-chain resilience is being bolstered through India-based manufacturing hubs, even as oral and injectable GLP-1 entrants from Novo Nordisk and Eli Lilly compete for regulatory clearances and market capacity amid pricing-reform risks and potential production delays.

Confidence in Eli Lilly’s GLP-1 obesity and diabetes treatments is surging on strong clinical data, bullish analyst ratings, strategic inventory builds, and an expanding pipeline, though some worry about intense competition and reliance on a few blockbuster drugs.